- Trading of Sonnet BioTherapeutics Holdings Inc SONN stock was halted thrice during the early morning session.
- No company-specific reports are driving up the stock price today, so it appears there are external factors at play.
- Discussions about Sonnet have floated on social media platforms like StockTwits, Twitter, and Discord.
- Investors on these platforms are citing the Company as being a short squeeze candidate.
- The clinical-stage biotech company focused on cancer therapeutics reported its Q3 FY21 results early this week.
- Price Action: SONN shares are up 151.0% at $1.87 during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
